Announcement of personnel change issued by 25 pharmaceutical enterprises of jinsanyin

[China Pharmaceutical network industry trends] Jin Sanyin 4, many people will choose to leave and change jobs at this stage, and many enterprises will also have large and small personnel changes According to the statistics of relevant data, in March, a total of 25 pharmaceutical companies issued the announcement of personnel changes Among them, 19 pharmaceutical executives chose to leave, including Jiang Xin, director and chairman of China Pharmaceutical; Xia Jun, director of Kunming Pharmaceutical Group; LV Zhiyuan, director and deputy general manager of Sinopharm; Congfan, general manager of Xiaer China, etc The author has carried on the correlation arrangement, and has selected the partial pharmaceutical enterprise's announcement On March 9, Zhou Xinji and Wu Anjun of Bikang Co., Ltd resigned from relevant positions, and Bikang Co., Ltd issued a personnel change announcement In view of the resignation of Zhou Xinji, the former chairman of the company, the company decided to elect Gu Xiaojia as the chairman of the company At the same time, Gu Xiaojia resigned as chairman of the board of supervisors for work reasons, and the company decided to elect Li Jingkun as chairman of the board of supervisors In addition, Wu Anjun applied to resign from the relevant positions of the company's director, vice president, financial director and subordinate companies due to work adjustment After resignation, Wu Anjun will no longer hold any post in the company and its subsidiaries, and intends to hold relevant post in Xinyi Bikang new pharmaceutical industry complex Investment Co., Ltd., the controlling shareholder of the company Feng Dong of Medtronic Greater China went to Sydney to start a new job On March 12, Medtronic Greater China announced that Feng Dong, vice president of Greater China heart and vascular business group (CVG), was transferred to vice president of CVG in Asia Pacific region The business layer reported to Mike Coyle, global president of CVG, and the regional layer reported to Li xilie, President of Asia Pacific region Feng Dong will go to Sydney on May 1 to start a new job CVG will be replaced by Lin Song, the current Vice President of heart rhythm and heart failure (crhf) in Greater China Jiang Xin resigned from relevant positions on March 14, China Pharmaceutical announced that due to work adjustment, Jiang Xin resigned from relevant positions of the company's director, chairman and special committee of the board of directors and no longer held any position in China Pharmaceutical Upon the recommendation of the controlling shareholders and the deliberation and approval of the 13th meeting of the 7th board of directors, Gao Yuwen was elected by the board of directors as the chairman of China pharmaceutical, whose term of office expires at the end of this board of directors On the same day, Gao Yuwen resigned as the general manager of the company due to work adjustment, and the company appointed Hou Wenling as the general manager of the company until the expiration of the current board of directors Sun Guorui left MSD on March 20 MSD officially announced that sun Guorui, director of broad market development, had decided to leave the company at the end of March to seek external development opportunities Before the new successor is recruited, Zhang Cheng, the managing director of MSD and the head of business operation, will take charge of the broad market team According to the announcement issued by pharmaceutical on March 31, sun Bing requested to resign as secretary of the 8th board of directors and CFO of the company due to job transfer After resigning, sun Bing no longer holds any position in the company During the period when the company's board of directors appoints a new secretary to the board of directors, Huang Wei, the company's chief financial officer, shall temporarily act as secretary of the board of directors for a period not exceeding three months Conclusion: in 2018, pharmaceutical market, policies and other factors will also affect the development of pharmaceutical enterprises In order to seek a larger and broader market space, the strategy of pharmaceutical enterprises is bound to make corresponding adjustments, and then the personnel changes of enterprises, pharmaceutical people also need to meet more new opportunities and challenges It can be seen that this year, personnel adjustment in pharmaceutical enterprises will be more frequent, and we will pay close attention to personnel changes in pharmaceutical enterprises.